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A b s t r A c t
Patients with ST-segment elevation myocardial infarction (STEMI) and multi-vessel 
coronary disease (MVD) have poorer outcomes after primary percutaneous coro-
nary intervention (PCI) compared to those with one-vessel disease. Current STEMI 
guidelines recommend revascularization of the infarct related artery (IRA) only 
during primary PCI, while PCI for non-IRA lesions should be performed after ob-
jective evidence of residual ischemia. Evidence regarding the optimal management 
strategy for non-IRA lesions in STEMI patients with MVD has been limited and 
mainly based on retrospective, contradictory and probably biased data. The recently 
published PRAMI randomized study challenges the guidelines since preventive acute 
multi-vessel PCI for significant stenoses in non-IRAs has been associated with a re-
duction of major adverse cardiovascular events (MACE) compared to PCI limited to 
the IRA. A review of the literature and a discussion about the implications of PRAMI 
study regarding the optimal revascularization strategy for STEMI with MVD are pre-
sented herein.
I n t r o d u c t I o n
Primary percutaneous coronary intervention (PCI) is currently the reperfusion 
treatment of choice in acute ST-segment elevation myocardial infarction (STEMI).1,2 
Due to the diffuse nature of the atherosclerosis among patients with STEMI 30% to 
60% have multi-vessel coronary artery disease (MVD).3,4 Continuous advancements in 
interventional techniques and adjuvant antithrombotic treatment have led to significant 
improvement in primary PCI procedural success, but still patients with MVD have 
poorer outcomes compared to those with one-vessel disease.4,5 This can be explained 
by more diffuse coronary atherosclerosis, left ventricular dysfunction extending into 
the non-infarct zone and an increased systemic inflammatory response with endothelial 
dysfunction, vasospasm and impaired flow in non-culprit vessels.6-9
Current STEMI guidelines recommend revascularization of the infarct-related 
artery (IRA) only during primary PCI, while PCI of non-IRAs is not recommended.1,2 It 
is also stated that decisions about PCI of non-culprit lesions should be taken later and 
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only guided by objective evidence of residual ischemia.10 Only 
for patients in cardiogenic shock may PCI be performed for all 
critical lesions of large epicardial coronary arteries as it could 
contribute to reduced border zone ischemia and improved 
survival.11,12 In addition, when more than one culprit lesions 
are suspected acute multi-vessel PCI might also be beneficial.3
s t e M I  A n d  M v d : 
s t r A t e g I e s  f o r  n o n - I r A  L e s I o n s
Current evidence on the optimal management of non-IRA 
lesions in STEMI patients is limited and mainly based on retro-
spective and probably biased data. Treatment strategies range 
from a conservative approach with primary PCI of only the 
IRA and subsequent optimal medical therapy unless recurrent 
ischemia occurs to an aggressive approach with treatment of 
all significant lesions in the acute phase of primary PCI. The 
mainstream approach stands between these two extremes 
and is the one of staged procedures with the IRA treated 
acutely and other lesions treated later during the hospital 
stay or within 30-60 days following discharge (Fig. 1).13 For 
the time being there are no definite scientific answers about 
their relative merits, while each approach has advantages and 
disadvantages (Table 1).14
The conservative approach makes sense and current PCI 
guidelines recommend optimal medical treatment or ischemia-
driven PCI of non-culprit lesions.15 As for patients with stable 
coronary artery disease (CAD) in case of intermediate lesions 
non-invasive ischemia tests and fractional flow reserve (FFR) 
measurements could guide additional revascularization pro-
cedures.15,16 However, the systemic inflammatory reaction 
following STEMI can increase protease activity and destabilize 
atherosclerotic plaques, which explains why recurrent throm-
botic events tend to cluster shortly after and often involve 
lesions not responsible for the initial presentation.17,18 In this 
context complete revascularization, acutely or staged, may 
have advantages since plaque instability may not be limited to 
the IRA only. In patients with STEMI and MVD incomplete 
revascularization has been shown to be a strong and independ-
ent risk factor for death and major adverse cardiac events 
(MACE).19 To the contrary complete revascularization has 
been associated with better long-term prognosis.3
Especially, immediate revascularization may reduce the 
risk of recurrent events by limiting myocardial injury and 
consequent systemic inflammation, whereas revascularization 
after completion of an infarct does not generally confer such 
a benefit. On the other hand, a weakened fibrous cap alone 
does not suffice to precipitate plaque rupture and not all 
plaques that rupture have thin fibrous caps.20 Furthermore, 
performing acutely multi-vessel PCI can result in stenting 
clinically irrelevant lesions, based simply on the “oculosten-
fIgure 1. Current revascularization approaches for STEMI and MVD. MVD = multivessel (coronary artery) disease; STEMI = 
ST- elevation myocardial infarction.
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tAbLe 1. Advantages and disadvantages of different strategies for PCI revascularization in STEMI with multivessel 
(MV) coronary artery disease (CAD) regarding several issues (+: advantage,  -- : disadvantage).
Acute Mv PcI IrA-only & ischemia driven PcI IrA-only & staged PcI
Complete revascularization + -- +
Repeated procedures + -- --
Ischemia producing lesions + -- +
Multiple disrupted plaques + -- +
Double myocardial jeopardy -- + +
Stent thrombosis risk -- + +
Unnecessary stenting -- + +
PCI time, radiation, contrast -- + +
Risk/benefit assessment, 
Heart Team approach
-- + +
Patient comfort + -- --
Hospital time/costs + -- --
otic’’ assessment of the operator without objective evidence of 
myocardial ischemia. To add complexity to the issue, Hanratty 
et al reported that 21% of lesions initially assessed as >50% 
during infarct angiography became <50% during angiography 
performed later.21 Moreover, Dambrink et al showed that in-
farct angiography overestimated the severity of non-culprit le-
sions and when FFR was performed it revealed that 40% of the 
non-culprit lesions did not show hemodynamic significance.22 
Finally, important arguments against performing multi-vessel 
PCI acutely in STEMI are the augmented risk of additional 
PCI due to the pro-thrombotic and inflammatory milieu, the 
contrast load and the degraded left ventricular function in the 
acute phase. Any potential PCI complications in the non-IRA 
may lead to catastrophic consequences (double myocardial 
jeopardy) including peri-procedural death. In an observational 
study of STEMI patients undergoing PCI, the predicted prob-
ability of contrast induced nephropathy increased from 10.9% 
to 27.5% for patients with lowest to highest quartile of the 
contrast volume and patients who developed nephropathy had 
significantly higher in-hospital mortality.23
Some of the abovementioned risks of acute multi-vessel 
PCI can be limited by staged procedures, which is currently 
the mainstream approach to obtain complete revascularization 
after primary PCI for STEMI.13 There are decades of possible 
scenarios based on combinations of angiographic and clinical 
findings in individual patients and decisions for revasculariza-
tion often demand complex thinking and time. The advantage 
for staged PCI is that intervention on non-culprit lesions can be 
discussed within a Heart Team to determine the best individual 
management strategy.10,15
A c u t e  M u L t I - v e s s e L  P c I  d u r I n g 
n o n - s h o c K  s t e M I  I n  P r A c t I c e
Because on limited evidence different opinions exist on the 
use of acute multi-vessel PCI for STEMI across centers and 
operators. Whereas retrospective studies report unfavorable 
outcomes and guidelines discouraging acute multi-vessel PCI 
during non-shock STEMI, multi-vessel PCI remains rela-
tively common in practice. A recent analysis of the National 
Cardiovascular Data Registry database found incidences of 
multi-vessel PCI in acute STEMI ranging between 0% and 
38% among participating centers.24 In the HORIZONS-AMI 
study 18.5% of patients underwent multi-vessel PCI but only 
1.5% had cardiogenic shock.25 In the APEX AMI trial, 9.9% 
of patients underwent multi-vessel PCI but only 1.0% was in 
Killip class IV (cardiogenic shock).26 In the New York State 
Registry, 12.5% underwent multi-vessel PCI, but only 4.4% 
met the definitions of hemodynamic compromise.27 
The use of acute multi-vessel PCI in 10% to 20% of STEMI 
cases may be the result of two opposite clinical scenarios. 
Firstly, this aggressive strategy may be selected in an unfavora-
ble setting. Non-culprit vessel PCI for critical lesions might be 
pursued even in hemodynamically stable patients in case of 
persisting chest pain and/or significant residual ST-segment 
elevation (Fig. 2). Identification and treatment of the culprit 
lesion is not always easy in patients with multi-vessel disease, 
especially in the presence of multiple critical lesions, small 
culprit vessels or total occlusions receiving collateral circula-
tion. In some patients, a chronic occlusion may be attempted 
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first and subsequently another vessel will be attempted when 
the error is recognized. It should not be forgotten that in 
some cases identifying a single culprit lesion in the presence 
of multi-vessel disease may be hampered by the variable abil-
ity of the electrocardiogram to localize infarctions.28 All these 
factors may cause delayed or unsuccessful reperfusion and 
contribute to adverse prognosis. Alternatively, this strategy 
may be selected sometimes in a favorable setting where suc-
cessful culprit vessel stenting has been readily accomplished 
during a smooth procedure. If another easy to treat target 
lesion is identified in this patient, the temptation to finish 
the procedure achieving complete revascularization might be 
high. Conversely, complex lesions requiring long procedures 
would discourage the operator to prolong the acute PCI after 
treating the IRA.
A c u t e  M u L t I - v e s s e L  P c I  I n  s t e M I : 
t h e  L I t e r A t u r e
Existing data are somewhat conflicting and controversial 
(Table 2). 
I )  s t u d I e s  s u P P o r t I n g  I r A - o n Ly  P c I
Several retrospective studies have demonstrated that 
multi-vessel PCI during the course of STEMI is harmful and 
thus support the conservative approach of IRA-only PCI in 
the acute STEMI phase.
Corpus et al described significantly higher risk of re-
infarction (13% vs 2.8%, p=0.001), repeat revascularization 
(25% vs 15%, p = 0.007) and MACE (40% vs 28%, p = 
0.006) with acute multi-vessel PCI (152 patients) compared 
to IRA-only PCI (354 patients).29 Cavender et al examined 
the U.S. National Cardiovascular Data Registry from 2004 
to 2007 to identify STEMI patients with MVD undergoing 
primary PCI.24 In-hospital mortality of 3134 patients (10.8%) 
with acute multi-vessel PCI was compared with that of the 
remaining 25802 patients undergoing IRA intervention only. 
Patients with multi-vessel intervention during primary PCI 
were at higher risk and more likely presented in cardiogenic 
shock. Overall, the in-hospital mortality rate was higher in 
patients undergoing acutely multi-vessel PCI. The increased 
in-hospital mortality persisted after adjustment for potential 
confounders and surprisingly, even among patients presenting 
with cardiogenic shock. 
Toma et al after a secondary analysis of the APEX-AMI 
trial found acute multi-vessel PCI to be performed only in 9.9% 
of patients with STEMI and multi-vessel disease. Ninety-day 
death and death/congestive heart failure/shock were higher in 
this group compared with the IRA-only PCI group (12.5% vs 
5.6%, p <0.001 and 17.4% vs 12.0%, p= 0.02, respectively). 
After adjusting for patient and procedural characteristics, 
as well as propensity for performing acute multi-vessel PCI, 
this procedure remained independently associated with an 
increased hazard of 90-day mortality (adjusted hazard ratio 
2.44, p <0.001).26
I I )  s t u d I e s  s u P P o r t I n g  I r A - o n Ly  P c I 
f o L L o w e d  b y  s t A g e d  P c I  o f  n o n - I r A s
Data from several studies support staged PCI after IRA-only 
primary PCI, which is currently the mainstream approach to ob-
tain complete revascularization after primary PCI for STEMI.13
fIgure 2. Example of a patient with 3-vessel coronary artery disease presenting with anterior STEMI and treated with acute multi-
vessel PCI. After successful PCI of the left anterior descending artery it was necessary to treat a critical lesion of the marginal branch 
at the same procedure in order to stabilize the patient. The right coronary artery was not treated acutely despite consecutive signifi-
cant lesions since angiographically they seemed stable and PCI in this tortuous artery would be complex. Staged PCI was performed 
3 weeks later to complete revascularization. A. Before acute PCI. b. After acute PCI. c. Right coronary artery at initial presentation. 
PCI = percutaneous coronary intervention.
PREVENTIVE PCI IN STEMI
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In a small single-center study, Rigattieri et al found that 
in STEMI patients IRA-only PCI with subsequent medical 
treatment has better early outcomes, whereas early (same 
admission) staged multi-vessel PCI is associated with fewer 
MACE at follow-up (mean length: 13 months) at a cost of 
a higher incidence of in-hospital MACE, mainly driven by 
peri-procedural myocardial infarction during the elective 
procedure.30 
Based on the New York State PCI Registry, Hannan et al 
reported that in hemodynamically stable patients with MVD, 
acute phase multi-vessel PCI results in an increased in-hospital 
mortality when compared with IRA-only PCI (2.4% vs 0.9%, 
p=0.04). On the contrary, patients undergoing staged multi-
vessel PCI within 60 days after the index procedure had a 
significantly lower 12-month mortality rate than patients 
undergoing IRA-only PCI (1.3% vs 3.3%, p = 0.04).27 In a 
post-hoc cohort analysis of the HORIZONS-AMI trial, Kor-
nowski et al reported that multi-vessel PCI was associated with 
a higher 1-year mortality (9.2% vs 2.3.%) and stent thrombosis 
rate (5.7% vs 2.3%) than staged PCI.25 
Finally, based on data from the Western Denmark Heart 
Registry, Jensen et al examined mortality according to timing 
of multi-vessel PCI in a cohort of 1174 patients with STEMI 
and MVD.31 The adjusted hazard ratios for one-year mortality 
were 1.53 for acute multi-vessel PCI, 0.60 for staged procedure 
during the index hospitalization and 0.28 for staged procedure 
performed within 60 days, compared to patients with single 
vessel disease. Thus, acute multi-vessel PCI in patients with 
STEMI was associated with increased mortality, while staged 
procedures were associated with superior survival outcomes.31
I I I )  s t u d I e s  s u P P o r t I n g  A c u t e  
M u L t I - v e s s e L  P c I 
Some retrospective and small prospective studies suggest 
that acute multi-vessel PCI during STEMI could be beneficial 
and thus support such an aggressive approach.
In a single-center registry, Chen et al compared outcomes 
between patients with myocardial infarction (STEMI or non-
STEMI) who underwent multi-vessel PCI within 7 days (239 
patients; 202 in one procedure, 37 with staged procedures) 
and patients who underwent treatment of the IRA alone (n = 
1145).32 The multi-vessel PCI group had a significantly higher 
prevalence of adverse prognostic indicators, yet the observed 
1-year survival and event rates were similar between the two 
groups.32
Kong et al analyzed patients undergoing PCI for STEMI 
(632 with multi-vessel PCI and 1350 with IRA only PCI) from 
the New York State Angioplasty Registry database (years 
2000–2001). The highest risk patients (previous myocardial 
infarction, PCI, bypass surgery, or cardiogenic shock) were 
excluded. In-hospital mortality was lower (0.8% vs 2.3%, 
p=0.018) in the multi-vessel PCI group. No differences were 
observed in other ischemic complications, renal failure, or 
length of stay. After multivariate analysis, multi-vessel PCI 
remained a significant predictor of lower in-hospital death 
(odds ratio = 0.27, p= 0.03).33
In a small single-center registry, Varani et al found among 
745 STEMI patients that acute multi-vessel PCI is feasible and 
safe. This study described the relative proportions of the three 
most frequently used strategies for revascularization in STEMI 
with multi-vessel disease: IRA-only primary PCI (39%), staged 
PCI (24%), and acute multi-vessel PCI (37%). Mortality at 30 
days was 6.3% for IRA-only PCI versus 2.8% for multi-vessel 
PCI (p = 0.023), without differences if in a single (3.3%) or 
in staged session (2.2%).34 In a similar small study, Qarawani 
et al reported a decrease in recurrent infarctions or ischemia 
but no survival benefit with acute multi-vessel PCI compared 
to IRA-only PCI.35
Jaguszewski and colleagues recently analyzed the Swiss 
AMIS Plus registry for in-hospital outcome of patients un-
dergoing single-vessel or multi-vessel PCI during the acute 
primary PCI procedure.36 Rates of multi-vessel PCI were 
greater among the three categories of high-risk patients (out-
of-hospital cardiac arrest, class Killip III/IV and left main 
involvement). Overall, in-hospital mortality after acute multi-
vessel PCI was higher when compared with IRA-only PCI 
(7.3% vs 4.4%; p<0.001). However, this result was not present 
when patients were stratified by risk; in-hospital mortality for 
multi-vessel PCI vs IRA only PCI was 2% vs 2% (p=1.00) in 
low-risk patients and 22.2% vs 21.7% (p=1.00) in high-risk 
patients. Thus, one can conclude that acute multi-vessel PCI 
is not per se harmful compared to IRA-only primary PCI and 
that acute complete revascularization is potentially beneficial 
in reducing costs and being more patient-friendly.36,37
Despite rigorous adjustments using complex statistics 
the abovementioned retrospective studies suffer from the 
potential for residual bias caused by unmeasured confound-
ers. Some small prospective studies also challenge current 
recommendations and suggest that the strategy of acute multi-
vessel PCI in STEMI could be beneficial.38-40 Di Mario et al 
in the HELP-AMI multi-center, randomized trial assigned 
69 STEMI patients with multi-vessel disease to unbalanced 
randomization with culprit-lesion only and then staged PCI 
(n = 17) versus complete acute multi-vessel PCI (n = 52).38 
They found acute multi-vessel PCI to be safe despite requiring 
longer procedures and larger amounts of contrast, with a trend 
for lower revascularization requirements at 12 months and 
no economic advantages. They acknowledged, however, that 
the staged approach avoids treating lesions unnecessarily.38 
In a prospective single-center study, Khattab et al found no 
mortality benefit and no difference in MACE at one year with 
acute multi-vessel PCI compared to staged PCI.40 In a more 
recent study, Politi et al randomized 214 STEMI patients with 
MVD to IRA-only PCI (n = 84), simultaneous treatment of 
non-IRA lesions (n = 65) or IRA-only PCI followed by staged 
revascularization (n=65). In-hospital mortality, unplanned 
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re-hospitalization and repeat revascularization occurred more 
frequently with the IRA-only PCI strategy which emerged as 
an independent predictor of adverse events.39 Although the 
results of these prospective studies are provocative, they were 
significantly underpowered to detect differences in death or 
recurrent myocardial infarction. Furthermore, the requirement 
for repeat revascularization in case of the IRA-only PCI should 
not be considered a MACE, since a closer clinical follow-up 
is needed compared to the other approaches. 
M e t A n A L y s e s
Three metanalyses of studies comparing preventive acute 
complete revascularization in STEMI to culprit-only primary 
PCI were published in 2011.6,41,42 The metanalysis of Sethi et al 
analyzed 9 non randomized studies (including 31853 patients) 
and 2 small randomized studies that were added in secondary 
analysis. Long-term mortality and MACE were found similar 
for both strategies.41 A second metanalysis by Bangalore at al 
included 19 studies (23 arms) that evaluated 61764 patients 
with STEMI and MVD similarly concluded that acute multi-
vessel PCI appeared to be safe compared to culprit-only PCI.6 
In the metanalysis by Vlaar et al, which analyzed 14 retrospec-
tive and four prospective studies involving 40280 patients, the 
results of the large cohort studies seem to disagree with the 
results of smaller prospective studies.42 Pooled results of 9 
retrospective cohort studies of 5128 patients suggested higher 
long-term mortality after acute multi-vessel PCI than after 
IRA-only PCI, whereas pooled results of 3 prospective studies 
of 288 patients suggested no difference. Pairwise metanalyses 
demonstrated that staged PCI was associated with lower short- 
and long-term mortality as compared with IRA-only PCI and 
acute multi-vessel PCI and that acute multi-vessel PCI was 
associated with the highest mortality rates at both short- and 
long-term follow-up. In network analyses, staged PCI was 
also consistently associated with lower mortality.42 The results 
of the meta-analysis by Vlaar et al show that a staged PCI 
should be the preferred approach and appear to contradict 
the conclusions of the other two contemporary metanalyses, 
which suggest no difference in long-term mortality rates after 
multi-vessel PCI or IRA-only PCI.6,41 These discordant findings 
could be attributed to methodological differences, which is a 
common phenomenon for metanalyses conducted at about 
the same time by different investigators.43
P r A M I  s t u d y :  r e s u L t s  A n d  c o M M e n t s
After considering the abovementioned published data 
one concludes that in STEMI with MVD the appropriateness 
of additional PCI procedures of apparently significant yet 
asymptomatic non-culprit lesions is highly debatable with only 
limited and conflicting evidence. The most recently published 
randomized trial showed a significant reduction of MACE in 
the acute multi-vessel “preventive” PCI group compared to 
the IRA-only PCI plus optimal medical therapy group.44 The 
objective of the Preventive Angioplasty in Myocardial Infarc-
tion trial (PRAMI) was to determine whether preventive 
PCI performed during the same procedure as the IRA PCI 
would be beneficial. A total of 465 consecutive patients with 
acute STEMI and MVD were enrolled in this randomized, 
multi-center, single-blind study. MVD was defined as >50% 
stenosis in one or more non-infarct arteries suitable for PCI. 
Patients were excluded in case of cardiogenic shock, prior 
coronary artery bypass graft surgery, >50% stenosis in either 
the left main or ostia of both the left anterior descending and 
circumflex arteries or if the only non-IRA stenosis was a total 
occlusion. The patients were randomized after successful 
emergency PCI to preventive PCI (n=234) or no preventive 
PCI (n=231) in non-IRAs while they were still in the cath-
eterization laboratory. The trial was stopped prematurely due 
to a highly significant difference in the primary outcome in 
favor of preventive PCI (p<0.001). The mean follow-up was 
23 months. The primary composite outcome (a composite of 
death from cardiac causes, non-fatal myocardial infarction, 
or refractory angina) occurred in 21 patients in the preven-
tive PCI group (9%) and 53 patients in the no preventive PCI 
group (22.9%), with a risk reduction of 65% in the preventive 
PCI group (hazard ratio-HR 0.35; 95% confidence intervals-
CI, 0.21-0.58, p<0.001). This translates into an absolute risk 
reduction of 14% or a number needed to treat of 7 patients to 
prevent one primary endpoint event at 1 year. Cardiac death 
or non-fatal myocardial infarction occurred in 11 (4.7%) pa-
tients in the preventive PCI group and 27 (11.7%) patients in 
the no preventive PCI group (HR 0.36; 95% CI 0.18 – 0.73, 
p=0.004). This translates into an absolute risk reduction of 
7% or a number needed to treat of 15 patients to prevent one 
cardiac death or nonfatal MI at 1 year. There was no differ-
ence between the two groups concerning procedure related 
complications, however the trial was not adequately powered 
for safety outcomes.
These robust results in favor of preventive acute-multi 
vessel PCI in STEMI are opposite to current standards of 
care and the PRAMI study is subject to criticism for several 
reasons.45-47 Patients were eligible if the culprit lesion had 
been treated successfully and there was ≥50% stenosis in one 
or more coronary arteries other than the IRA considered by 
the cardiologist as treatable by PCI. However, most studies 
define a stenosis as clinically significant if ≥70%, except for 
the left main artery. More recent guidelines define significant 
coronary disease as lesions >70% by angiography, or lesions 
that are hemodynamically significant by stress testing, FFR, 
or intravascular ultrasound.10 Furthermore, there was no 
core laboratory confirmation and the severity and location of 
the stenoses or the left ventricular ejection fraction were not 
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reported, which may lead to a misinterpretation of the results 
of the study. More patients who did not undergo preventive 
PCI had diabetes and anterior STEMI, which are important 
predictors of poor outcomes. As a result, it is possible that 
patients in the IRA-only PCI group were sicker than those in 
the preventive PCI group. Also patients who did not undergo 
preventive PCI would be more likely to report symptoms which 
would increase the recorded incidence of refractory angina and 
lead to more testing. By study design staged PCI in patients 
without angina was discouraged and further PCI should be 
performed only in cases of refractory angina and after objec-
tive assessment of ischemia. Thus acute multi-vessel PCI was 
not compared to a staged PCI strategy which is however the 
current mainstream approach for STEMI with MVD. The 
SWISSI II randomized trial found staged elective (non-acute) 
PCI to be superior to medical therapy for patients with proven 
silent myocardial ischemia after STEMI.48 In a recent report 
by Dangas et al, staged PCI was the revascularization strategy 
in 80% of patients with STEMI and MVD, additional PCI 
in case of symptoms or ischemia in 14% of cases and acute 
multi-vessel PCI in only 2% of cases.13 Finally, in PRAMI study 
2428 STEMI patients were screened but only 465 (about one 
out of five) were found eligible. Thus, the results of PRAMI 
study would be applicable to a minority of STEMI patients. 
Similar results should be replicated in other studies and the 
characteristics of STEMI patients that could benefit from acute 
preventive PCI should be precisely defined before considering 
preventive acute PCI for STEMI as a legitimate option.
w h A t  t o  d o  w I t h  n o n - c u L P r I t 
L e s I o n s  I n  s t e M I  A n d  M v d ?
The reduction in rates of cardiac death, myocardial infarc-
tion, or refractory angina by stenting of significant lesions in 
non IRAs could have two possible explanations. It can be ob-
tained either by reducing ischemia from flow-limiting stenoses 
or by stabilizing unstable coronary lesions. The distinction is 
important because it would affect the optimal technique to 
identify the lesions that should be treated. 
If benefit was confined to flow-limiting lesions, target-
ing of more severe stenoses or lesions selected by FFR may 
be preferred, with little gain from stenting less severe and 
non-flow-limiting stenoses. Complete revascularization using 
FFR testing to identify significant lesions has been shown to 
improve outcomes compared with revascularization based 
only on angiographic analysis.16,49 Flow-limiting lesions may be 
identified at the time of STEMI since FFR at time of primary 
PCI has been shown to correlate well with FFR obtained later 
when the patient is stablilized.50 Thus, FFR can be considered 
during the acute phase, but the results should be prudently 
used to support a decision for staged PCI.50
On the other hand, if benefit is derived by treating lesions at 
risk because of instability, the measurement of FFR may have 
limited value, while consideration of angiographic appear-
ances (e.g., lesion irregularity and ulceration), intravascular 
ultrasound and optical coherence tomography may better 
help target non-culprit lesions for stenting. In the prospective 
angiographic – intravascular ultrasound PROSPECT study in-
volving patients undergoing PCI for acute coronary syndromes, 
most non-culprit lesions responsible for follow-up MACE 
were angiographically mild at baseline and more likely to be 
characterized by a plaque burden ≥70%, a minimal luminal 
area ≤4 mm2 or to be classified on the basis of virtual histology 
as thin-cap fibroatheromas.18 However, non-culprit lesions 
with all three of the above characteristics were associated with 
MACE in only 18.2% of cases, which is an argument against 
stenting lesions that would be named “vulnerable” based on 
the above criteria.18 Thus, for the time being the evidence base 
for the selection of flow-limiting lesions by FFR is solid, which 
is not the case for “vulnerable” plaque detection by various 
intravascular imaging criteria (virtual histology, optical coher-
ence tomography-OCT, near-infrared spectroscopy) where 
more research is needed.51
c o n c L u s I o n s
Current practice guidelines do not support acute multi-
vessel PCI during non-shock STEMI. This concept is chal-
lenged by the recently published PRAMI study where pre-
ventive multi-vessel PCI in STEMI has been associated with 
reduction of MACE compared to the conservative approach 
of IRA-only PCI. Multi-vessel PCI may be necessary in some 
STEMI patients who have multiple critical lesions and do not 
improve after IRA-only PCI. This kind of patients probably 
could explain the results of the PRAMI trial, which however 
has limitations and has been subject to criticism. The results 
of ongoing randomized controlled trials are expected in order 
to clarify the optimal revascularization strategy after the IRA 
PCI for patients with STEMI and MVD.52
MVD in STEMI is not a single entity and thus the 
treatment approach should be individualized.4 A decisional 
algorithm is proposed (Fig. 3). Primary PCI of the IRA still 
remains the default strategy in non-shock STEMI according 
to the guidelines and despite the PRAMI study results. Acute 
multi-vessel PCI could be justified in patients with multiple 
critical lesions. Significant lesions of the non-infarct arteries 
should be timely treated by staged PCI procedures that should 
be justified because of symptoms or positive functional tests.
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